Press Releases

Press Releases

ImCheck Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022

|   Science & Medicine
  • Broad antitumor immune responses and demonstration of durable disease control from solid tumor patients who…

Read more

ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline

|   Financial & Business
  • Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of…

Read more

ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022

|   Science & Medicine
  • Continued positive safety data across a range of ICT01 doses in 69 cancer patients and updated efficacy data from 22…

Read more

ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01

|   Science & Medicine

EVICTION trial proceeds to Phase IIa based on promising Phase I patient data for ICT01 across a broad range of solid…

Read more

For the third year in a row, ImCheck has been awarded by the French Tech as one of the top 120 French start-ups/scale-ups and among 7 French biotech developing innovative therapies

|   Leadership & Corporate

ImCheck has been recognized again as one of the top 120 French start-ups and scale-ups based on performance criteria…

Read more

ImCheck to Present at 40th Annual J.P. Morgan Healthcare Conference

|   Science & Medicine

ImCheck Therapeutics announced today that its Chief Executive Officer, Pierre d’Epenoux, will present a corporate…

Read more

ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021

|   Science & Medicine
  • Oral presentation includes positive safety data across a wide range of ICT01 doses and efficacy data from patients…

Read more

ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Gamma-delta T Cells in Science Translational Medicine

|   Science & Medicine
  • Publication underscores ImCheck’s pioneering role in Vγ9Vδ2 T cell-based immunotherapy capable of bridging to the…
Read more

ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021

|   Science & Medicine

ImCheck Therapeutics today announced that it will present updated clinical data from the ongoing EVICTION Phase I/IIa…

Read more

ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021

|   Science & Medicine
  • First EVICTION data from checkpoint inhibitor-refractory solid tumor patients treated in the first two…
Read more

ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021

|   Science & Medicine

ImCheck Therapeutics today announced that it will present updated clinical data from the ongoing EVICTION Phase I/IIa…

Read more

ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells

|   Science & Medicine
  • First published study showing the role and sequential interaction of butyrophilin subtypes in the induction of…
Read more

ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01

|   Science & Medicine
 EVICTION is a multi-center trial evaluating Butyrophilin 3A-targeted activation of the anti-tumor immune response of…
Read more

ImCheck Therapeutics Appoints Dr. Loui Madakamutil, Noted Expert in Immunology and Autoimmune Diseases, as Chief Scientific Officer

|   Leadership & Corporate

ImCheck Therapeutics today announced the appointment of Loui Madakamutil, PhD, as Chief Scientific Officer (CSO). Dr.…

Read more

Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response

|   Science & Medicine
  • ICT01 activates γ9δ2 T cells that rapidly migrate out of the circulation and secrete IFNγ and TNFα leading to an…

Read more

ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021

|   Science & Medicine

ImCheck Therapeutics today announced that it will present  clinical data from the ongoing EVICTION Phase I/IIa clinical…

Read more

For a second year, ImCheck has been selected by the French Tech as one of the top 120 French startups and of the 9 biotech companies developing innovative therapies

|   Leadership & Corporate

Repeating its selection in 2020, ImCheck has again been recognized as one of the top 120 French startups based on…

Read more

ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01

|   Science & Medicine

Preliminary EVICTION Phase I/IIa trial data shows butyrophilin-targeted mAb ICT01’s dose-dependent and specific…

Read more

ImCheck Announces Four ICT01 Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting

|   Science & Medicine

Marseille, France, October 14, 2020ImCheck Therapeutics today announced the acceptance of four clinical and…

Read more

ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €54 million ($64 million)

|   Financial & Business

ImCheck Therapeutics today announced that it has secured an additional €6 million ($7.1 million) from BB Pureos…

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subscribe to receive our press releases and related news